



JOIN THE TYVASO (Support Program)

For the treatment of pulmonary arterial hypertension (WHO Group 1), Tyvaso can improve the ability to exercise in people who also take bosentan (an ERA) or sildenafil (a PDE-5 inhibitor)



Just Prescribed Tyvaso

Your doctor has prescribed Tyvaso to help treat your pulmonary arterial hypertension (PAH). Now you may be wondering what comes next. Your doctor has put in a referral, or application, for your Tyvaso prescription. To ensure you get the help and support you need, Specialty Pharmacy Services (SPS) will be responsible for working with your insurance company or provider to process the referral.

What is a Specialty Pharmacy Services provider?

Specialty Pharmacy Services (SPS) providers are different from the local pharmacy you normally visit. They will work with you and your healthcare team to coordinate many aspects of your care. This includes step-by-step training on how to use Tyvaso, and delivery of your prescription and supplies. This service is designed to provide you with ongoing support. Through your SPS provider, you can expect phone calls, automatic refills, and access to a 24-hour hotline.

The Tyvaso Inhalation System is available only through the following SPS providers:


a medco company
PHONE: 1-866-344-4874
FAX: 1-800-711-3526
www.accredo.com


PHONE: 1-877-242-2738
FAX: 1-877-943-1000
www.cvsspecialty.com

"I really enjoy helping them overcome some of their fears and providing a little comfort."

– D.T., Tyvaso Mentor

[Meet all the Tyvaso Mentors](#)

Here is what you can expect while you wait for treatment to begin:



REFERRAL—Your doctor has put in an application, or referral, for your Tyvaso prescription with an SPS provider. Your SPS provider will be your one-stop resource for support with Tyvaso. They will work with you and your healthcare team to coordinate many aspects of your care.



INSURANCE—The SPS will be responsible for working with your insurance company to process the application or referral.



CONFIRMATION—Your insurance company may require confirmation that you have PAH. This may include a documentation of procedures, such as a [right heart catheterization](#) (RHC), which is necessary to confirm your PAH diagnosis and to access Tyvaso.



DEMONSTRATION—Prior to your initial start date, your SPS nurse may contact you to schedule an appointment at your doctor's office or home to teach you how to use Tyvaso.



APPROVAL—The SPS will notify you of your insurance company's approval and discuss any uncovered costs.



START TREATMENT—Your healthcare or SPS provider will contact you to coordinate the date and location for you to start using Tyvaso—do not start treatment with Tyvaso until you have completed your training and be sure to talk to your healthcare or SPS provider if you have any questions.

Note: This is a general overview of the SPS process and may vary based on individual circumstances or need.

[Next: Get Important Information If You're Just Starting Tyvaso](#)

IMPORTANT SAFETY INFORMATION FOR TYVASO

- Tyvaso is breathed in (inhalable) through your mouth into your lungs. Tyvaso should only be used with the Tyvaso Inhalation System.

Before you take Tyvaso, tell your healthcare provider about all of your medical conditions, including if you:

- Have a lung disease (such as asthma or chronic obstructive pulmonary disease (COPD)).
- Have a lung infection.
- Have liver or kidney problems, as your ability to tolerate Tyvaso may be affected.
- Have low blood pressure, as Tyvaso may cause symptomatic hypotension (low blood pressure).
- Are pregnant or plan to become pregnant. It is not known if Tyvaso will harm your unborn baby. Women who can become pregnant should use effective birth control while taking Tyvaso.
- Are breast-feeding or plan to breast-feed. It is not known if Tyvaso passes into your breast milk.

It is important to tell your healthcare provider about all the medicines you may be taking, including prescription and non-prescription medicines, vitamins, and herbal supplements, as they may affect your use of Tyvaso by increasing the risk of side effects or decreasing effectiveness. Especially tell your healthcare provider if you take any of these medicines:

- Medicines that decrease blood clotting such as warfarin or heparin, as Tyvaso reduces the ability of your blood to clot (coagulate), and increases your risk for bleeding if you are taking blood thinners (anticoagulants).
- Diuretics (water pills), antihypertensives (medications used to treat high blood pressure or heart disease), or other vasodilators (medications that lower blood pressure), as Tyvaso may increase your risk for hypotension (low blood pressure).
- Gemfibrozil such as Lopid (for high cholesterol) or rifampin such as Rimactane, Rifadin, Rifamate or Rifater (for infection), as your

Tyvaso dosage may need adjustment.

The most common side effects of Tyvaso are coughing, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), and fainting or loss of consciousness. These are not all the possible side effects of Tyvaso. Tell your healthcare provider about any side effects that bother you or do not go away. Your healthcare provider may be able to help you manage the side effects.

INDICATION

Tyvaso is a prescription medicine used in adults to treat pulmonary arterial hypertension (PAH) (WHO Group 1), which is high blood pressure in the arteries of your lungs. Tyvaso can improve exercise ability in people who also take bosentan (an endothelin receptor antagonist, (ERA)) or sildenafil (a phosphodiesterase-5 (PDE-5) inhibitor). Your ability to do exercise decreases 4 hours after taking Tyvaso.

The effects of Tyvaso are unknown in patients under 18 years of age.

TYVISIdtcJUN16

Please see the [Full Prescribing Information](#), [Patient Package Insert](#), and the Tyvaso Inhalation System [Instructions for Use manual](#).

For additional information about Tyvaso, visit www.tyvaso.com or call 1-877-UNITHER (1-877-864- 8437).

Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.

This information is provided for an informational purpose and is not intended as treatment advice. Patients should consult a healthcare professional for treatment advice.

[FAQs](#) | [Important Safety Information](#) | [Full Prescribing Information](#) | [Patient Package Insert](#) | [Instructions for Use manual](#) | [Site Map](#) | [Contact Us](#) | [Privacy Policy](#) | [Terms of Use](#) | [About United Therapeutics](#) | [Unsubscribe](#)



Tyvaso is a registered trademark of United Therapeutics Corporation. All other trademarks and registered trademarks are the property of their respective owners.

© 2016 United Therapeutics Corporation. All rights reserved. US/TYV/AUG15/354b

This site is intended for use by US residents only.